124 related articles for article (PubMed ID: 18981463)
1. Randomized, phase II study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced soft tissue sarcoma.
Baker LH; Rowinsky EK; Mendelson D; Humerickhouse RA; Knight RA; Qian J; Carr RA; Gordon GB; Demetri GD
J Clin Oncol; 2008 Dec; 26(34):5583-8. PubMed ID: 18981463
[TBL] [Abstract][Full Text] [Related]
2. Phase 2 study of ABT-510 in patients with previously untreated advanced renal cell carcinoma.
Ebbinghaus S; Hussain M; Tannir N; Gordon M; Desai AA; Knight RA; Humerickhouse RA; Qian J; Gordon GB; Figlin R
Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6689-95. PubMed ID: 18006769
[TBL] [Abstract][Full Text] [Related]
3. Phase I safety, pharmacokinetic, and pharmacodynamic study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced cancer.
Hoekstra R; de Vos FY; Eskens FA; Gietema JA; van der Gaast A; Groen HJ; Knight RA; Carr RA; Humerickhouse RA; Verweij J; de Vries EG
J Clin Oncol; 2005 Aug; 23(22):5188-97. PubMed ID: 16051960
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of the antiangiogenic agent SU5416 in patients with advanced soft tissue sarcomas.
Heymach JV; Desai J; Manola J; Davis DW; McConkey DJ; Harmon D; Ryan DP; Goss G; Quigley T; Van den Abbeele AD; Silverman SG; Connors S; Folkman J; Fletcher CD; Demetri GD
Clin Cancer Res; 2004 Sep; 10(17):5732-40. PubMed ID: 15355900
[TBL] [Abstract][Full Text] [Related]
5. Phase I study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 with 5-fluorouracil and leucovorin: a safe combination.
Hoekstra R; de Vos FY; Eskens FA; de Vries EG; Uges DR; Knight R; Carr RA; Humerickhouse R; Verweij J; Gietema JA
Eur J Cancer; 2006 Mar; 42(4):467-72. PubMed ID: 16406507
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and toxicity of the angiogenesis inhibitor SU5416 as a single agent in patients with advanced renal cell carcinoma, melanoma, and soft tissue sarcoma.
Kuenen BC; Tabernero J; Baselga J; Cavalli F; Pfanner E; Conte PF; Seeber S; Madhusudan S; Deplanque G; Huisman H; Scigalla P; Hoekman K; Harris AL
Clin Cancer Res; 2003 May; 9(5):1648-55. PubMed ID: 12738717
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of 9-nitro-camptothecin in patients with advanced chordoma or soft tissue sarcoma.
Chugh R; Dunn R; Zalupski MM; Biermann JS; Sondak VK; Mace JR; Leu KM; Chandler WF; Baker LH
J Clin Oncol; 2005 May; 23(15):3597-604. PubMed ID: 15908670
[TBL] [Abstract][Full Text] [Related]
8. Brostallicin, an agent with potential activity in metastatic soft tissue sarcoma: a phase II study from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
Leahy M; Ray-Coquard I; Verweij J; Le Cesne A; Duffaud F; Hogendoorn PC; Fowst C; de Balincourt C; di Paola ED; van Glabbeke M; Judson I; Blay JY;
Eur J Cancer; 2007 Jan; 43(2):308-15. PubMed ID: 17095209
[TBL] [Abstract][Full Text] [Related]
9. A phase II study of ABT-510 (thrombospondin-1 analog) for the treatment of metastatic melanoma.
Markovic SN; Suman VJ; Rao RA; Ingle JN; Kaur JS; Erickson LA; Pitot HC; Croghan GA; McWilliams RR; Merchan J; Kottschade LA; Nevala WK; Uhl CB; Allred J; Creagan ET
Am J Clin Oncol; 2007 Jun; 30(3):303-9. PubMed ID: 17551310
[TBL] [Abstract][Full Text] [Related]
10. Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study.
Lorigan P; Verweij J; Papai Z; Rodenhuis S; Le Cesne A; Leahy MG; Radford JA; Van Glabbeke MM; Kirkpatrick A; Hogendoorn PC; Blay JY;
J Clin Oncol; 2007 Jul; 25(21):3144-50. PubMed ID: 17634494
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of sequential high-dose doxorubicin and ifosfamide compared with standard-dose doxorubicin in patients with advanced soft tissue sarcoma: an open-label randomized phase II study of the Spanish group for research on sarcomas.
Maurel J; López-Pousa A; de Las Peñas R; Fra J; Martín J; Cruz J; Casado A; Poveda A; Martínez-Trufero J; Balañá C; Gómez MA; Cubedo R; Gallego O; Rubio-Viqueira B; Rubió J; Andrés R; Sevilla I; de la Cruz JJ; Del Muro XG; Buesa JM
J Clin Oncol; 2009 Apr; 27(11):1893-8. PubMed ID: 19273704
[TBL] [Abstract][Full Text] [Related]
12. Exatecan in pretreated adult patients with advanced soft tissue sarcoma: results of a phase II--study of the EORTC Soft Tissue and Bone Sarcoma Group.
Reichardt P; Nielsen OS; Bauer S; Hartmann JT; Schöffski P; Christensen TB; Pink D; Daugaard S; Marreaud S; Van Glabbeke M; Blay JY;
Eur J Cancer; 2007 Apr; 43(6):1017-22. PubMed ID: 17336054
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of intravenous TZT-1027 in patients with advanced or metastatic soft-tissue sarcomas with prior exposure to anthracycline-based chemotherapy.
Patel S; Keohan ML; Saif MW; Rushing D; Baez L; Feit K; DeJager R; Anderson S
Cancer; 2006 Dec; 107(12):2881-7. PubMed ID: 17109446
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study.
Schiller JH; Larson T; Ou SH; Limentani S; Sandler A; Vokes E; Kim S; Liau K; Bycott P; Olszanski AJ; von Pawel J
J Clin Oncol; 2009 Aug; 27(23):3836-41. PubMed ID: 19597027
[TBL] [Abstract][Full Text] [Related]
15. Preclinical evaluation of antiangiogenic thrombospondin-1 peptide mimetics, ABT-526 and ABT-510, in companion dogs with naturally occurring cancers.
Rusk A; McKeegan E; Haviv F; Majest S; Henkin J; Khanna C
Clin Cancer Res; 2006 Dec; 12(24):7444-55. PubMed ID: 17189418
[TBL] [Abstract][Full Text] [Related]
16. Thrombospondin-1 mimetic peptide inhibitors of angiogenesis and tumor growth: design, synthesis, and optimization of pharmacokinetics and biological activities.
Haviv F; Bradley MF; Kalvin DM; Schneider AJ; Davidson DJ; Majest SM; McKay LM; Haskell CJ; Bell RL; Nguyen B; Marsh KC; Surber BW; Uchic JT; Ferrero J; Wang YC; Leal J; Record RD; Hodde J; Badylak SF; Lesniewski RR; Henkin J
J Med Chem; 2005 Apr; 48(8):2838-46. PubMed ID: 15828822
[TBL] [Abstract][Full Text] [Related]
17. Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme.
Reardon DA; Fink KL; Mikkelsen T; Cloughesy TF; O'Neill A; Plotkin S; Glantz M; Ravin P; Raizer JJ; Rich KM; Schiff D; Shapiro WR; Burdette-Radoux S; Dropcho EJ; Wittemer SM; Nippgen J; Picard M; Nabors LB
J Clin Oncol; 2008 Dec; 26(34):5610-7. PubMed ID: 18981465
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of daily oral perifosine in patients with advanced soft tissue sarcoma.
Bailey HH; Mahoney MR; Ettinger DS; Maples WJ; Fracasso PM; Traynor AM; Erlichman C; Okuno SH
Cancer; 2006 Nov; 107(10):2462-7. PubMed ID: 17058289
[TBL] [Abstract][Full Text] [Related]
19. Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors.
Eskens FA; Steeghs N; Verweij J; Bloem JL; Christensen O; van Doorn L; Ouwerkerk J; de Jonge MJ; Nortier JW; Kraetzschmar J; Rajagopalan P; Gelderblom H
J Clin Oncol; 2009 Sep; 27(25):4169-76. PubMed ID: 19636022
[TBL] [Abstract][Full Text] [Related]
20. Prospective study of thrombospondin-1 mimetic peptides, ABT-510 and ABT-898, in dogs with soft tissue sarcoma.
Sahora AI; Rusk AW; Henkin J; McKeegan EM; Shi Y; Khanna C
J Vet Intern Med; 2012; 26(5):1169-76. PubMed ID: 22816494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
